^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IGF1R overexpression

i
Other names: IGF1R, CD221, IGFIR, IGFR, JTK13, MGC18216, Insulin-like growth factor 1 receptor
Entrez ID:
Related biomarkers:
over1year
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IGF1R (Insulin-like growth factor 1 receptor) • BAX (BCL2-associated X protein) • MIR331 (MicroRNA 331)
|
BCL2 expression • IGF1R overexpression • BAX expression • miR-331 expression
over1year
Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins. (ASCO 2023)
This strategy optimizes cancer cell-specific delivery to block proliferation and immune checkpoints. The results support further preclinical proof-of-concept studies to enable an eIND submission for the anti-miR-21 RNA-peptide analog.
PARP Biomarker • IO biomarker
|
IGF1R (Insulin-like growth factor 1 receptor) • MIR21 (MicroRNA 21)
|
IGF1R overexpression
almost2years
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227. (PubMed, Front Med (Lausanne))
This review will detail experience using the alpha emitter radium-223 (Ra, tradename Xofigo), that targets bone formation, in osteosarcoma, specifically related to patient selection, use of gemcitabine for radio-sensitization, and using denosumab to increasing the osteoblastic phenotype of these cancers. A case of an inoperable left upper lobe vertebral-paraspinal-mediastinal osteoblastic lesion treated successfully with Ra combined with gemcitabine is described. Because not all areas of osteosarcoma lesions are osteoblastic, but nearly all osteosarcoma cells overexpress IGF1R, and some subsets expressing Her-2, the anti-IGF1R antibody FPI-1434 linked to actinium-225 (Ac) or the Her-2 antibody linked to thorium-227 (Th) may become other means to provide targeted alpha particle therapy against osteosarcoma (NCT03746431 and NCT04147819).
Review • Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
HER-2 expression • IGF1R expression • IGF1R overexpression
|
gemcitabine • Prolia (denosumab) • Xofigo (radium Ra-223 dichloride) • FPI-1434
almost2years
The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. (PubMed, Clin Cancer Res)
We demonstrate that combined trametinib and ganitumab is effective in a genomically diverse panel of RAS-mutated FN RMS preclinical models.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • RAS (Rat Sarcoma Virus)
|
PTEN mutation • RAS mutation • IGF1R expression • IGF1R overexpression
|
Mekinist (trametinib) • ganitumab (AMG 479)
2years
A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer. (PubMed, Biochem Pharmacol)
On the other hand, MEK (mitogen-activated protein kinase kinase)1/2 inhibitors, including PD0325901, selumetinib, trametinib and TAK-733, selectively antagonized IGF1R signaling-mediated antiestrogen resistance but did not affect cell proliferation under normal growth conditions. In a group of 219 patients with metastasized ER+ breast cancer, strong pMEK staining showed a significant correlation with no clinical benefit of first-line tamoxifen treatment. We propose a critical role for MEK activation in IGF1R signaling-mediated antiestrogen resistance and anticipate that dual-targeted therapy with a MEK inhibitor and antiestrogen could improve treatment outcome.
Journal
|
ALK (Anaplastic lymphoma kinase) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • IGF1R (Insulin-like growth factor 1 receptor)
|
ER positive • EGFR overexpression • IGF1R expression • IGF1R overexpression
|
Mekinist (trametinib) • tamoxifen • Koselugo (selumetinib) • mirdametinib (PD-0325901) • REC-4881
2years
Different Roles of the Insulin-like Growth Factor (IGF) Axis in Non-small Cell Lung Cancer. (PubMed, Curr Pharm Des)
In this review, we summarize the biological roles of the IGF axis in NSCLC, including the expression and prognostic significance of the related components, noncoding RNA regulation, involvement in drug resistance, and therapeutic application. This review offers a comprehensive understanding of NSCLC and provides insightful ideas for future research.
Journal
|
IGF1 (Insulin-like growth factor 1) • IGF2 (Insulin-like growth factor 2) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1)
|
IGF1R overexpression
2years
The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer. (PubMed, BMC Cancer)
IGF-1R and Livin are associated with CRC tumorigenesis and might be valuable for novel biomarker identification and targeted therapeutic strategy development.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • IGF1R overexpression • IGF1 elevation
over2years
IGF2BP2 promotes gastric cancer progression by regulating the IGF1R-RhoA-ROCK signaling pathway. (PubMed, Cell Signal)
We emphasized the oncogenic role of IGF2BP2 in gastric carcinogenesis and confirmed its activation is partly due to the activation of IGF1R-RhoA-ROCK signaling pathway. Our findings identified that IGF2BP2 might be a promising prognostic biomarker and provided clinical translational potential.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IGF1R (Insulin-like growth factor 1 receptor) • IGF2 (Insulin-like growth factor 2) • RHOA (Ras homolog family member A) • IGFBP2 (Insulin-like growth factor binding protein 2) • IL1B (Interleukin 1, beta) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF1R expression • IGF1R overexpression
over2years
CircRASSF2 promotes IGF1R and osteosarcoma metastasis via sponging miR-6838-5p. (PubMed, Ann Transl Med)
In conclusion, the promoting effects of IGF1R on OS are targeted by miR-6838-5p. CircRASSF2 restored the expression of IGF1R by sponging miR-6838-5p, thereby promoting the progression of OS.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R expression • IGF1R overexpression
over2years
Differential Receptor Tyrosine Kinase Phosphorylation in the Uterus of Rats Following Developmental Exposure to Tetrabromobisphenol A. (PubMed, Toxicol Res Appl)
The downstream effector, phospho-MAPK44/42 was also increased in uteri of treated rats. Our findings show RTKs are dysregulated following early life TBBPA exposures and their sustained activation may contribute to TBBPA-induced uterine tumors observed in rats later in life.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FLT1 (Fms-related tyrosine kinase 1) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • TYK2 (Tyrosine Kinase 2) • EPHB2 (EPH Receptor B2) • IR (Insulin receptor)
|
HER-2 overexpression • EGFR overexpression • IGF1R overexpression
almost3years
Expression of Insulin-like Growth Factor Type 1 Receptor is Linked to Inflammation in Adamantinomatous Craniopharyngioma. (PubMed, Neuroendocrinology)
Picropodophyllin, a specific inhibitor of IGF1R, increased the expression of p-ERK protein, and decreased the transcription level of interleukin-6...The high expression of IGF1R in tumor cell stem-like cells might inhibit the expression of p-ERK and promote the generation of inflammatory factors. Insulin-like growth factor type 1 receptor plays a stemness maintenance role in ACP and regulates the production of inflammatory factors through a p-ERK pathway, which suggests that targeting IGF1R and p-ERK might provide a new direction for alleviating tumor inflammation.
Journal
|
IL6 (Interleukin 6) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IGF1R (Insulin-like growth factor 1 receptor) • CD44 (CD44 Molecule)
|
IGF1R expression • IGF1R overexpression • CD44 expression • CTNNB1 expression • IL6 expression
|
picropodophyllin (AXL1717)
almost3years
miR-99a inhibits proliferation and migration of cervical cancer cells by targeting IGF1R. (PubMed, J BUON)
miR-99a can specifically inhibit IGF1R expression and thus inhibit the proliferation and migration of CCCs.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • MIR99A (MicroRNA 99a)
|
IGF1R expression • IGF1R overexpression • miR-99a expression
3years
Vorinostat triggers miR-769-5p/3p-mediated suppression of proliferation and induces apoptosis via the STAT3-IGF1R-HDAC3 complex in human gastric cancer. (PubMed, Cancer Lett)
Our studies suggest that miR-769-5p/miR-769-3p acts as a tumor suppressor by the STAT3-IGF1R-HDAC3 complex. Moreover, SAHA triggers miR-769-5p/miR-769-3p-mediated inhibition of proliferation and induces apoptosis in GC cells.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR769 (MicroRNA 769)
|
IGF1R overexpression • miR-769 expression
|
Zolinza (vorinostat)
3years
lncRNA SNHG11 facilitates prostate cancer progression through the upregulation of IGF‑1R expression and by sponging miR‑184. (PubMed, Int J Mol Med)
The results of rescue experiments demonstrated that IGF‑1R overexpression reversed the suppressive effects of SNHG11 knockdown on the proliferation, migration and invasion of PCa cells. On the whole, the findings of the present study suggest that SNHG11 expression is upregulated in PCa and that it facilitates PCa progression, at least in part, via the modulation of the miR‑184/IGF‑1R signaling axis.
Journal
|
MIR184 (MicroRNA 184)
|
IGF1R overexpression
over3years
Nuclear IGF1R interacts with NuMA and regulates 53BP1‑dependent DNA double‑strand break repair in colorectal cancer. (PubMed, Oncol Rep)
Bright‑field PLA analysis on a paraffin‑embedded tissue microarray from patients with colorectal cancer revealed a significant association between increased nuclear colocalizing signals of NuMA‑53BP1 and a shorter overall survival. These results indicate that nIGF1R plays a role in facilitating 53BP1‑dependent DDR by regulating the NuMA‑53BP1 interaction, which in turn might affect the clinical outcome of patients with colorectal cancer.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
IGF1R overexpression
over3years
Long non-coding RNA DUXAP8 promotes tumorigenesis by regulating IGF1R via miR-9-3p in hepatocellular carcinoma. (PubMed, Exp Ther Med)
Moreover, miR-9-3p as the target of DUXAP8 and IGF1R as the target of miR-9-3p were verified in HCC cells. lncRNA DUXAP8 contributed to HCC tumorigenesis via the miR-9-3p/IGF1R axis, providing a novel therapeutic approach for HCC diagnosis and treatment.
Journal
|
CDH1 (Cadherin 1) • IGF1R (Insulin-like growth factor 1 receptor) • VIM (Vimentin)
|
IGF1R overexpression • CDH1 expression • VIM expression
over3years
CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. (PubMed, Prostate Cancer Prostatic Dis)
In summary, we found that CASC11 is upregulated in PCa cells and clinical tumor samples in comparison to corresponding controls and revealed that ectopic CASC11 overexpression promotes cellular phenotypes associated with PCa progression through CASC11/miR-145/IGF1R axis.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R expression • IGF1R overexpression
over3years
Long noncoding RNA LINC01291 promotes the aggressive properties of melanoma by functioning as a competing endogenous RNA for microRNA-625-5p and subsequently increasing IGF-1R expression. (PubMed, Cancer Gene Ther)
In addition, loss of LINC01291 decreased the chemoresistance of melanoma cells to cisplatin...Rescue experiments revealed that the roles induced by LINC01291 depletion in melanoma cells could be reversed by suppressing miR-625-5p or overexpressing IGF-1R. Our study identified the LINC01291/miR-625-5p/IGF-1R competing endogenous RNA pathway in melanoma cells, which may represent a novel diagnostic biomarker and an effective therapeutic target for melanoma.
Journal
|
MIR625 (MicroRNA 625)
|
IGF1R overexpression
|
cisplatin
over3years
Clinicopathological significance of insulin-like growth factor-1 receptor expression in breast cancer. (PubMed, Ann Ital Chir)
Overexpression of IGF1R was found to be directly correlated with shorter DFS and OS as well as some clinicopathological features associated with adverse prognosis such as higher Ki67 index, mitotic count, tumor grade, presence of geographic necrosis, HER2 positivity, ER negativity, HER2+ molecular subtype, histological tumor type of IDC rather than ILC. Thus, IGF1R might be considered as an useful target for comprehensive future anti-tumor therapy investigations. Additionally, using IGF1R as well as Ki67 as a part of routine pathology practice might be fruitful in breast cancer therapy and prediction of prognosis.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • IGF1R (Insulin-like growth factor 1 receptor)
|
HER-2 positive • HER-2 overexpression • HER-2 expression • ER negative • IGF1R expression • IGF1R overexpression
almost4years
[VIRTUAL] Genomics of Multiple Myeloma Influences the Expression of CAR T-Cell Targets (ASH 2020)
Furthermore, our results provide a roadmap for immunotherapy of MM by unbiasedly comparing the expression of top MM cell surface targets in patient data and normal cells and suggest that the genetic landscape of MM may predict the expression of specific targets for precision immunotherapy. The quest for novel MM targets for immunotherapies remains open, and CAR target discovery driven by specific genetic events remains an active area of investigation.
CAR T-Cell Therapy • IO biomarker
|
CD74 (CD74 Molecule) • IGF1R (Insulin-like growth factor 1 receptor) • CD44 (CD44 Molecule) • CD70 (CD70 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • ICAM1 (Intercellular adhesion molecule 1) • SDC1 (Syndecan 1)
|
Chr t(11;14) • Chr t(4;14) • Chr t(14;16) • CD70 expression • IGF1R overexpression • Chr t(14;20)
almost4years
MiR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer. (PubMed, Yakugaku Zasshi)
On the contrary, miR-520b can downregulate the expression of IGF-1R. miR-520b increases DOX sensitivity and promotes cell apoptosis in breast cancer by inhibiting IGF-1R expression by the PI3K/AKT signaling pathway.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R overexpression
|
doxorubicin hydrochloride
almost4years
Downregulation of Long Noncoding RNA Myocardial Infarction Associated Transcript Suppresses Cell Proliferation, Migration, Invasion, and Glycolysis by Regulation of miR-488-3p/IGF1R Pathway in Colorectal Cancer. (PubMed, Cancer Biother Radiopharm)
The present study confirmed that the "MIAT/miR-488-3p/IGF1R" pathway was involved in the development of CRC, which may be the target for developing therapeutic approaches for CRC.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R overexpression
almost4years
Upregulation of miR-133a-3p enhances Bufothionine-induced gastric cancer cell death by modulating IGF1R/PI3K/Akt signal pathway mediated ER stress. (PubMed, Life Sci)
Bufothionine promoted GC cell death by triggering miR-133a-3p/IGF1R/PI3K/Akt axis mediated ER stress and ROS production.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R overexpression
|
LY294002
4years
MicroRNA-139-5p modulates the growth and metastasis of malignant melanoma cells via the PI3K/AKT signaling pathway by binding to IGF1R. (PubMed, Cell Cycle)
The study validates that miR-139-5p could suppress malignant melanoma progression through the repression of the PI3K/AKT signaling pathway by down-regulating IGF1R. Therefore, miR-139-5p could pave a new way for the treatment of malignant melanoma.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • MIR139 (MicroRNA 139)
|
IGF1R overexpression • miR-139-5p expression
4years
Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. (PubMed, Anticancer Res)
In conclusion, IGF-MTX at 0.20 μM equivalents per kg was well tolerated, caused no cytopenia, and produced stable disease and extension of life.
P1 data • Clinical Trial,Phase I • Journal
|
IGF1R (Insulin-like growth factor 1 receptor) • CD34 (CD34 molecule) • IGF1 (Insulin-like growth factor 1)
|
IGF1R overexpression
|
methotrexate
4years
LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. (PubMed, Theranostics)
Our finding suggested decreased expression of XPO5 prevents maturation of miR-378a-3p, which leaded to the overexpression of IGF-1R and counteracted the effects of sorafenib-induced apoptosis. LXRα was able to activate miRNA-378a-3p transcription in HCC cells and could be a potential combinable treatment strategy with sorafenib to suppress HCC progression.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R overexpression
|
sorafenib
4years
111In and 225Ac-labeled cixutumumab for imaging and alpha particle radiotherapy of IGF-1R positive triple negative breast cancer. (PubMed, Mol Pharm)
Additionally, low specific activity radioimmunoconjugate led to complete tumor remission in 2/6 mice. The data suggest that efficacy of cixutumumab can be enhanced by radiolabeling with 225Ac at a low specific activity.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R overexpression
|
cixutumumab (IMC A12)
over4years
Activation of β1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival. (PubMed, Apoptosis)
In conclusion, we present a plausible mechanism for the interplay between TF and IGF-1R involving FVIIa, β1-integrins, Src family proteins, and caveolin-1. Our results increase the knowledge of diseases associated with TF and IGF-1R overexpression in general but specifically of TF-mediated signaling with focus on cell survival.
Journal
|
CCND1 (Cyclin D1) • IGF1R (Insulin-like growth factor 1 receptor) • IGF1 (Insulin-like growth factor 1)
|
IGF1R overexpression